# GLP-1 Drugs at the Start of Hemodialysis: Hospitalization and Death | This GLP A matched cohort of 2,492 pairs starting hemodialysis found GLP-1 use linked to 9% lower hospitalization and 17% lower mortality, against a prior literature of 388 patients. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/dialysis-the-evidence-base-just-grew Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # GLP-1 Drugs at the Start of Hemodialysis: Hospitalization and Death A matched cohort of 2,492 pairs starting in-center hemodialysis linked GLP-1 use to 9% lower hospitalization and 17% lower mortality. The prior literature was 388 patients, and a baseline gap is worth reading first. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 Evidence in dialysis patients · previously, all studies combined · 388 patients · this one cohort · 2,492 matched pairs · Hospitalization 9% lower. Mortality 17% lower. · And 98% of the treated group had diabetes, against 73% of controls. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched cohort followed 2,492 patients who started in-center hemodialysis while on a GLP-1 drug, against 2,492 who did not. - Hospitalization was 9% lower (IRR 0.91, 95% CI 0.87-0.96) and mortality 17% lower (IRR 0.83, 95% CI 0.73-0.95). - The two groups differed substantially before treatment: 98% of GLP-1 users had diagnosed diabetes against 73% of controls, and 76% had predialysis nephrology care against 67%. - The FLOW trial that motivated the question studied chronic kidney disease and did not include people on dialysis. This site reported not long ago that [the entire world literature on these drugs in dialysis patients was 388 people](https://thisglp.com/research/can-you-take-a-glp1-on-dialysis) across 19 studies. That is now out of date. A single matched cohort at a large dialysis organization has followed 2,492 patients who began in-center hemodialysis while on a GLP-1 drug, against an equal number who did not [\[1\]](https://thisglp.com/research/dialysis-the-evidence-base-just-grew#ref-1). The results point the same way as the rest of this literature. Hospitalization ran 9% lower (incidence rate ratio 0.91, 95% CI 0.87–0.96) and mortality 17% lower (IRR 0.83, 95% CI 0.73–0.95). Both are incidence rate ratios rather than hazard ratios, because hospitalization recurs and the model is counting episodes rather than time to a first one. Hospitalization as an outcome, and what it captures, is discussed further in [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease). Look at who was taking it before you read the effect Among patients on a GLP-1 drug at dialysis initiation, 98% had a diagnosis of diabetes against 73% of the comparison group, 76% had received predialysis nephrology care against 67%, and mean BMI was 33 against 30. Predialysis nephrology care is one of the best-established predictors of doing well on dialysis and has nothing to do with any drug — it means someone was seen, planned for and started in an orderly way. Matching and adjustment narrow a gap like that; they do not close it. The reason this question was open at all is worth stating precisely, because it is easy to assume it was already answered. The FLOW trial showed semaglutide reducing kidney and cardiovascular outcomes in chronic kidney disease with type 2 diabetes — but it studied people whose kidneys were failing, not people whose kidneys had failed. End-stage disease on dialysis is a different physiological state, a different drug-clearance situation and a different population, which is why an entire literature of 388 patients existed alongside a major positive trial. What this cohort supplies is scale rather than certainty. Thirteen times the previous evidence base, pointing in a plausible direction, from data an organization already held — and with a baseline imbalance large enough that the honest summary is encouraging rather than established. A randomized trial in dialysis patients remains the thing that would settle it, and the same structure of argument applies to every observational result on this site, including [the sickle cell cohort](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease) and [the kidney disease evidence](https://thisglp.com/research/semaglutide-and-kidney-disease). For anyone in this situation the practical point is narrow: the question is now one a nephrologist can discuss with actual numbers rather than with an admission that nothing has been studied. That is a meaningful change even though nothing has been proved. ## Frequently asked Did the FLOW trial not already cover this? No. FLOW studied chronic kidney disease with type 2 diabetes and did not include people on dialysis. End-stage kidney disease is a different physiological state with different drug clearance. How strong is this evidence? It is much larger than anything before it and observational. The treated group differed notably at baseline — 98% versus 73% with diagnosed diabetes, and more predialysis nephrology care — which matching narrows without eliminating. What did it find? Among patients starting in-center hemodialysis, GLP-1 use was associated with a 9% lower hospitalization rate and a 17% lower mortality rate. ## Sources 1. \[1\] Karpinski S, Qazi R, Bjordahl T, Sibbel S, Weinhandl E, Tentori F, Brunelli SM (2026). Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease Clinical Journal of the American Society of Nephrology. [PMID 42640716](https://pubmed.ncbi.nlm.nih.gov/42640716/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)